These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21703474)

  • 21. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inhaled antibiotic therapy in other respiratory diseases].
    Baranda F; Gómez A; Gómez B
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():24-9. PubMed ID: 21703476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
    Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The future of inhaled antibiotic therapy. New products].
    Vendrell Relat M; Muñoz Castro G; Sabater Talaverano G; De Gracia Roldán J
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():30-2. PubMed ID: 21703477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of nebulized antibiotics in treating serious respiratory infections.
    Cole PJ
    J Chemother; 2001 Aug; 13(4):354-62. PubMed ID: 11589477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibiotic treatment of cystic fibrosis].
    de Montalembert M; Berche P; Lenoir G
    Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis.
    VanDevanter DR; Ballmann M; Flume PA
    Respir Med; 2011 Dec; 105 Suppl 2():S18-23. PubMed ID: 22208544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [How should chronic Pseudomonas aeruginosa bronchial infection be treated in the course of cystic fibrosis?].
    Hubert D; Desmazes-Dufeu N; Dusser D
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S129-35. PubMed ID: 12910145
    [No Abstract]   [Full Text] [Related]  

  • 37. Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients.
    Bauernfeind A; Hörl G; Przyklenk B
    Scand J Gastroenterol Suppl; 1988; 143():99-102. PubMed ID: 3164518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
    Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.